Acrivon Therapeutics, Inc. financial data

Symbol
ACRV on Nasdaq
Industry
Pharmaceutical Preparations
Location
480 Arsenal Way, Suite 100, Watertown, MA
Fiscal year end
December 31
Latest financial report
10-K - Q4 2024 - Mar 27, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1.27K % -18.7%
Debt-to-equity 9.27 % +4.16%
Return On Equity -46.2 % -8.79%
Return On Assets -42.3 % -8.41%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 31.4M shares +38.5%
Common Stock, Shares, Outstanding 31.2M shares +38.7%
Entity Public Float 99.1M USD -37.2%
Common Stock, Value, Issued 31K USD +34.8%
Weighted Average Number of Shares Outstanding, Basic 33.8M shares +53.1%
Weighted Average Number of Shares Outstanding, Diluted 33.8M shares +53.1%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 64M USD +39%
General and Administrative Expense 25.2M USD +19.6%
Operating Income (Loss) -89.2M USD -32.9%
Nonoperating Income (Expense) 8.64M USD +28.7%
Net Income (Loss) Attributable to Parent -80.6M USD -33.4%
Earnings Per Share, Basic -2.38 USD/shares +13.1%
Earnings Per Share, Diluted -2.38 USD/shares +13.1%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 39.8M USD +10.6%
Assets, Current 182M USD +40%
Property, Plant and Equipment, Net 4.47M USD +28.5%
Operating Lease, Right-of-Use Asset 3.55M USD -19.8%
Other Assets, Noncurrent 1.65M USD +556%
Assets 197M USD +42.2%
Accounts Payable, Current 758K USD -85%
Liabilities, Current 17.2M USD +29.4%
Operating Lease, Liability, Noncurrent 2.59M USD -31.3%
Liabilities 19.8M USD +16%
Accumulated Other Comprehensive Income (Loss), Net of Tax 447K USD
Retained Earnings (Accumulated Deficit) -197M USD -69.2%
Stockholders' Equity Attributable to Parent 177M USD +45.9%
Liabilities and Equity 197M USD +42.2%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -17.1M USD -50.4%
Net Cash Provided by (Used in) Investing Activities 5.85M USD -37.3%
Common Stock, Shares Authorized 500M shares 0%
Common Stock, Shares, Issued 31.2M shares +38.7%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -11.4M USD -462%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 40M USD +9.85%
Deferred Tax Assets, Valuation Allowance 56.7M USD +78.4%
Deferred Tax Assets, Gross 57.9M USD +74%
Operating Lease, Liability 3.65M USD -21.5%
Depreciation 1.01M USD +87.7%
Payments to Acquire Property, Plant, and Equipment 815K USD +3160%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -80M USD -32.5%
Lessee, Operating Lease, Liability, to be Paid 4.15M USD -24.4%
Property, Plant and Equipment, Gross 6.43M USD +45.1%
Operating Lease, Liability, Current 1.06M USD +20.5%
Lessee, Operating Lease, Liability, to be Paid, Year Two 1.31M USD -0.3%
Lessee, Operating Lease, Liability, to be Paid, Year One 1.23M USD +0.49%
Operating Lease, Weighted Average Discount Rate, Percent 0.08 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 505K USD -40.2%
Lessee, Operating Lease, Liability, to be Paid, Year Three 1.21M USD -10.5%
Deferred Tax Assets, Operating Loss Carryforwards 15.7M USD +66.8%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 0 USD
Lessee, Operating Lease, Liability, to be Paid, Year Four 404K USD -66.3%
Operating Lease, Payments 300K USD 0%
Additional Paid in Capital 373M USD +57.1%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 1.27M USD -16.7%
Share-based Payment Arrangement, Expense 14.3M USD +23%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%